Details of the Drug Combination

General Information of Drug Combination (ID: DCKT16H)

Drug Combination Name
Bifemelane MK-4815
Indication
Disease Entry Status REF
Hepatoblastoma Investigative [1]
Component Drugs Bifemelane   DMU73F0 MK-4815   DMT9K74
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: HB3
Zero Interaction Potency (ZIP) Score: 9.823
Bliss Independence Score: 11.448
Loewe Additivity Score: 0.529
LHighest Single Agent (HSA) Score: 0.994

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Bifemelane
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Terminated [2]
Bifemelane Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Monoamine oxidase type A (MAO-A) TT3WG5C AOFA_HUMAN Modulator [2]
------------------------------------------------------------------------------------
Bifemelane Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [4]
------------------------------------------------------------------------------------
Indication(s) of MK-4815
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Investigative [3]

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 4-(O-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase. J Neurochem. 1988 Jan;50(1):243-7.
3 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
4 Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.